Everolimus denied due to quantity / dose limits by Kaiser Permanente?

Kaiser Permanente's specific coverage criteria for everolimus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Kaiser Limits Everolimus Quantities — and How to Appeal

Everolimus quantity limits from Kaiser are typically tied to the dosing regimens described in the FDA-approved prescribing label, which specifies dosing for each approved indication. Quantity-limit denials arise when the prescription as written requests an amount that exceeds Kaiser's authorized dispensing quantity per fill cycle, or when the total duration of requested therapy exceeds what Kaiser's policy covers for the specific indication. These limits are reviewable, and appeals succeed most often when the prescriber documents the clinical rationale for the quantity requested and ties it directly to the FDA-approved label.

## The Federal Appeal Framework

Under ACA §2719, quantity-limit denials are fully appealable. You have the right to internal appeal followed by independent external review (IRO) within four months of final internal denial. For urgent cases, request expedited review.

For self-funded employer plans, ERISA §503 requires written explanation of the denial criteria and a full-and-fair review. You are entitled to receive the specific clinical policy Kaiser applied.

## Why Quantity-Limit Denials Are Overturnable

Kaiser's quantity limits must be grounded in the FDA-approved prescribing label. If the quantity requested matches the dosing regimen described in the label for this indication, the denial lacks clinical basis. Common reasons appeals succeed include: - The prescriber's dosing reflects a dose adjustment documented in the FDA label (e.g., for organ impairment or drug interactions managed by the treating physician). - The quantity limit was applied based on a different indication than the one being treated. - The fill cycle limit creates an access gap that compromises continuous therapy, which is clinically documented as harmful.

## Documentation to Gather

• FDA prescribing label: The dosing section showing the authorized dose and schedule for this patient's specific indication. Print from DailyMed and highlight the relevant section.
• Prescriber's dosing rationale: A letter from the treating physician explaining why the quantity prescribed aligns with the FDA label for this patient's weight, organ function, and indication — without stating specific numbers in the appeal letter itself; those appear in the chart.
• Chart documentation supporting the dose: Relevant lab results (organ function), body measurements, and clinical notes that informed the prescribed dose and quantity.
• Dispensing records: If the quantity limit interrupts ongoing therapy, pharmacy fill records showing the treatment course to date.

## Criteria-Mapping Structure

| Kaiser Quantity-Limit Criterion | Evidence That the Requested Quantity Is Appropriate | |---|---| | [Copy from Kaiser's clinical policy or denial letter] | [FDA label section, prescriber letter, chart note with citation] |

## Practical Next Steps

1. Obtain the denial letter with the specific quantity limit and policy basis cited. 2. Compare the requested quantity to the current FDA prescribing label for the applicable indication. 3. Have the treating physician write a letter explaining how the quantity aligns with the label. 4. Attach the relevant FDA label sections and supporting chart documentation. 5. File the internal appeal with the criteria-mapping table. 6. If denied internally, escalate to independent external review promptly — IRO reviewers apply FDA labeling standards, not the plan's internal quantity parameters.